CAL
VKTX icon

Capital Analysts LLC’s Viking Therapeutics VKTX Stock Holding History

Capital Analysts LLC’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-197
Closed -$1K – 811
2020
Q3 		$1K Hold
197
– – ﹤0.01% 745
2020
Q2 		$1K Hold
197
– – ﹤0.01% 693
2020
Q1 		$1K Hold
197
– – ﹤0.01% 671
2019
Q4 		$2K Hold
197
– – ﹤0.01% 679
2019
Q3 		$1K Hold
197
– – ﹤0.01% 680
2019
Q2 		$2K Hold
197
– – ﹤0.01% 643
2019
Q1 		$1K Hold
197
– – ﹤0.01% 640
2018
Q4 		$2K Buy
197
+144
+272% +$1.72K ﹤0.01% 554
2018
Q3 		$1K Buy
+53
New +$631 ﹤0.01% 555

Other funds holding VKTX

ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Capital Analysts LLC's VKTX Position: Q4 2020 in Review

Capital Analysts LLC sold out of Viking Therapeutics (VKTX) in Q4 2020, closing a stake of 197 shares — an estimated $1K sold.

Capital Analysts LLC first reported a position in VKTX in Q3 2018 and held it in 9 quarters. The position peaked at $2K in Q4 2019. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2020.

  • Capital Analysts LLC reported no remaining Viking Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Capital Analysts LLC sold 197 Viking Therapeutics shares in Q4 2020, an estimated $1K.
  • Capital Analysts LLC first reported a position in Viking Therapeutics in Q3 2018 and held it in 9 quarters.
  • Capital Analysts LLC's Viking Therapeutics position peaked at $2K in Q4 2019.
  • 143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.